Ecully, France

Colin Mansfield

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Colin Mansfield: Innovator in ALS Treatment

Introduction

Colin Mansfield is a notable inventor based in Ecully, France. He has made significant contributions to the field of medicine, particularly in the treatment of amyotrophic lateral sclerosis (ALS). His innovative approach has led to the development of a unique method for treating specific patient subpopulations afflicted with this challenging condition.

Latest Patents

Mansfield holds a patent for the use of masitinib in the treatment of a subpopulation of ALS patients. The patent, titled "Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation," discloses a method for treating patients with non-aggressive or moderately aggressive ALS. This method involves administering a tyrosine kinase inhibitor or mast cell inhibitor, specifically masitinib, or a pharmaceutically acceptable salt or solvate thereof. The treatment is particularly aimed at patients whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is less than 1.1 points per month.

Career Highlights

Colin Mansfield is associated with Ab Science, a company dedicated to the development of innovative therapies for serious diseases. His work at Ab Science has been instrumental in advancing treatment options for ALS patients. With a focus on targeted therapies, Mansfield's contributions are paving the way for improved patient outcomes.

Collaborations

Mansfield has collaborated with esteemed colleagues such as Alain Moussy and Jean-Pierre Kinet. These partnerships have fostered a collaborative environment that enhances research and development efforts in the field of ALS treatment.

Conclusion

Colin Mansfield's innovative work in the treatment of amyotrophic lateral sclerosis exemplifies the impact of targeted therapies in modern medicine. His patent for the use of masitinib represents a significant advancement in the fight against ALS, showcasing the potential for improved patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…